SIC
CYTK icon

SJS Investment Consulting’s Cytokinetics CYTK Stock Holding History

SJS Investment Consulting’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$597 Buy
7
+5
+250% +$359 ﹤0.01% 2209
2026
Q1 		$132 Sell
2
-120
-98% -$7.63K ﹤0.01% 2079
2025
Q4 		$7.75K Buy
122
+120
+6,000% +$7.46K ﹤0.01% 849
2025
Q3 		$110 Hold
2
– – ﹤0.01% 1573
2025
Q2 		$67 Sell
2
-1
-33% -$35 ﹤0.01% 1503
2025
Q1 		$121 Hold
3
– – ﹤0.01% 1501
2024
Q4 		$142 Sell
3
-12
-80% -$623 ﹤0.01% 1495
2024
Q3 		$792 Buy
15
+5
+50% +$279 ﹤0.01% 1153
2024
Q2 		$542 Buy
10
+5
+100% +$302 ﹤0.01% 1263
2024
Q1 		$351 Buy
5
+1
+25% +$77 ﹤0.01% 1394
2023
Q4 		$334 Buy
4
+1
+33% +$36 ﹤0.01% 1353
2023
Q3 		$89 Hold
3
– – ﹤0.01% 1557
2023
Q2 		$98 Hold
3
– – ﹤0.01% 1516
2023
Q1 		$106 Buy
+3
New +$122 ﹤0.01% 1455

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SJS Investment Consulting's CYTK Position: Q2 2026 in Review

SJS Investment Consulting increased its Cytokinetics (CYTK) stake by 250% in Q2 2026, buying an estimated $359 and bringing the position to 7 shares worth $597. The position accounts for ﹤0.01% of the portfolio, ranked #2209.

SJS Investment Consulting first reported a position in CYTK in Q1 2023 and has held it in 14 quarters since. The position peaked at $7.75K in Q4 2025. 188 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • SJS Investment Consulting held 7 shares of Cytokinetics worth $597 as of Q2 2026.
  • SJS Investment Consulting bought 5 Cytokinetics shares in Q2 2026, an estimated $359.
  • Cytokinetics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2209 holding.
  • SJS Investment Consulting first reported a position in Cytokinetics in Q1 2023 and has held it in 14 quarters since.
  • SJS Investment Consulting's Cytokinetics position peaked at $7.75K in Q4 2025.
  • 188 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.